Cargando…
Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial
BACKGROUND: Fluticasone furoate/Vilanterol trifenatate (FF/VI) is an inhaled corticosteroid/long-acting beta-agonist combination with a prolonged bronchodilator duration of action. We characterised the time-course of onset and offset of airway anti-inflammatory action of FF/VI, as assessed by fracti...
Autores principales: | Bardsley, George, Daley-Yates, Peter, Baines, Amanda, Kempsford, Rodger, Williams, Mathew, Mallon, Tony, Braithwaite, Irene, Riddell, Kylie, Joshi, Shashidhar, Bareille, Philippe, Beasley, Richard, Fingleton, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044077/ https://www.ncbi.nlm.nih.gov/pubmed/30001712 http://dx.doi.org/10.1186/s12931-018-0836-6 |
Ejemplares similares
-
Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy
por: Albertson, Timothy E, et al.
Publicado: (2016) -
Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial
por: Daley-Yates, Peter, et al.
Publicado: (2022) -
Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
por: Chen, Xia, et al.
Publicado: (2015) -
A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects
por: Kempsford, Rodger, et al.
Publicado: (2014) -
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)